alexa Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.


Advances in Oncology Research and Treatments

Author(s): Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C,

Abstract Share this page

Abstract Vascular endothelial growth factor (VEGF) is a potent mitogen for vascular endothelial cells. It has been associated with angiogenesis, growth, dissemination, metastasis, and poor outcome in solid tumors. To assess cellular VEGF levels and their prognostic significance in newly diagnosed acute myeloid leukemia (AML), we used a radioimmunoassay (RIA) to quantify VEGF levels in stored samples obtained before treatment from 99 patients with newly diagnosed AML treated at the MD Anderson Cancer Center from 1996 to 1998. Outcome in the 99 patients was representative of that observed in all patients seen at this institution with this diagnosis during these years, but the 99 patients had higher white blood cell (WBC) and blast counts than the other patients. Results of the RIA were confirmed by Western blot. There was a relationship between increasing VEGF levels and shorter survival (P =.01), as well as shorter disease-free survival, both from start of treatment and from complete response (CR) date. In contrast, there was no relationship between VEGF level and WBC or blast count, or between VEGF level and such established prognostic factors as age, cytogenetics, performance status, or presence of an antecedent hematologic disorder, and multivariate analysis indicated that VEGF was still prognostic for the above outcomes after accounting for these factors, as well as treatment. Our results suggest that at least in AML patients with higher WBC and blast counts, cellular VEGF level is an independent predictor of outcome.
This article was published in Blood and referenced in Advances in Oncology Research and Treatments

Relevant Expert PPTs

Relevant Speaker PPTs

  • Daniel S Peiffer
    Dietary consumption of black raspberries or their anthocyanin constituents alters innate immune cell trafficking in esophageal cancer
    PDF Version
  • Peter Weightman
    A new approach to the diagnosis of cervical, oesophageal and prostate cancer based on a combination of infrared and terahertz techniques
    PPT Version | PDF Version
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version